402948-37-2 Usage
General Description
Ethyl 2-[5-(4-methylpiperazinyl)benzimidazol-2-yl]acetate is a synthetic compound of significant interest in the field of chemistry. It consists of a benzimidazole ring—a form of organic compound made up of benzene and imidazole, a piperazine ring—a versatile organic compound used in several medicinal drugs, and an acetate ester. Additionally, it contains ethyl and methyl groups—common components in many organic compounds. The compound's complex structure and presence of various chemically-interacting rings make it a subject of investigation for potential pharmaceutical applications. However, specific properties, such as melting point, boiling point, and toxicity, can vary greatly depending on the precise arrangement and substitution of its atoms and must be determined through experimental testing.
Check Digit Verification of cas no
The CAS Registry Mumber 402948-37-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,0,2,9,4 and 8 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 402948-37:
(8*4)+(7*0)+(6*2)+(5*9)+(4*4)+(3*8)+(2*3)+(1*7)=142
142 % 10 = 2
So 402948-37-2 is a valid CAS Registry Number.
402948-37-2Relevant articles and documents
HPK1 inhibitor and application thereof
-
, (2019/05/16)
The invention belongs to the technical field of medicines, and specifically relates to an HPK1 inhibitor compound as shown in a formula (I) which is described in the specification or a pharmaceutically-acceptable salt and a stereoisomer of the HPK1 inhibi
TREATMENT OF MELANOMA
-
, (2008/12/07)
Methods of treating melanoma include administering a compound of Structure (I), a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt or the tautomer, or a mixture thereof to a subject. The comp
METHODS FOR TREATING DRUG RESISTANT CANCER
-
, (2008/06/13)
A method for treating drug-resistant cancer, includes: administering to a patient in need thereof, a compound of formula I, a tautomer of the compound, a salt of the compound, a salt of the tautomer, a mixture thereof, or a pharmaceutical composition comp